Applied DNA Sciences, Inc. (BNBX)
NASDAQ: BNBX · Real-Time Price · USD
3.800
+0.050 (1.33%)
At close: Oct 28, 2025, 4:00 PM EDT
3.830
+0.030 (0.79%)
After-hours: Oct 28, 2025, 5:44 PM EDT
Applied DNA Sciences Revenue
Applied DNA Sciences had revenue of $304.39K in the quarter ending June 30, 2025, a decrease of -35.62%. This brings the company's revenue in the last twelve months to $3.74M, up 55.60% year-over-year. In the fiscal year ending September 30, 2024, Applied DNA Sciences had annual revenue of $3.43M, down -74.33%.
Revenue (ttm)
$3.74M
Revenue Growth
+55.60%
P/S Ratio
0.19
Revenue / Employee
$77,980
Employees
48
Market Cap
4.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 3.43M | -9.94M | -74.33% |
| Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
| Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
| Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
| Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BNBX News
- 10 hours ago - BNBX Launches Digital Asset Treasury Dashboard and Provides Corporate Update - Business Wire
- 6 days ago - Applied DNA Sciences Closes up to $58 Million Private Placement; Announces Initial BNB Holdings Valued at Over $17 Million - Business Wire
- 22 days ago - Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX' Reflecting Digital Asset Treasury Strategy - Business Wire
- 4 weeks ago - Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation - Business Wire
- 5 weeks ago - Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences - Accesswire
- 2 months ago - Applied DNA Reports Third Quarter Fiscal 2025 Financial Results - Accesswire
- 3 months ago - Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application - Accesswire
- 4 months ago - Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements - Accesswire